ANPs drug is much further down the road. And in comparison has far less risk and is years closer to being marketable. It also already has ODD and a prv. I would hope upfront payment to be larger because of that for DMD.
LC and LG, if done as separate deals, could be like this.
The main difference is, they have a deal and we dont.
Controlling Cd49 is proving to have a far reach into many inflammation ailmsnts. We dont want it under valued.
ANPs drug is much further down the road. And in comparison has...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.001(1.35%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.5¢ | 7.3¢ | $25.98K | 350.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15553 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 146315 | 2 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
0.001 ( 1.35 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.5¢ | 7.3¢ | 48397 | ||
| Last updated 15.37pm 17/05/2024 ? | |||||
| PER (ASX) Chart |